Literature DB >> 18688079

Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report.

Agnieszka Piwowar1, Maria Knapik-Kordecka, Maria Warwas.   

Abstract

AIM: The main goal of the present study was the evaluation of ischemia-modified albumin (IMA) in patients with type 2 diabetes mellitus and estimation of its connection with vascular complications, glycemic control, hypertension, dyslipidemia and obesity.
METHODS: In 76 diabetic patients and 25 control subjects, a plasma level of IMA by manually performed, spectrophotometric Co(II)-albumin binding assay was determined. Other parameters such as glucose, fructosamine, HbA_{1c}, total cholesterol and its fractions (HDL, LDL), triglicerydes were estimated by routine methods.
RESULTS: Diabetic patients had significantly higher level of IMA in comparison with control subjects. There were not significant differences between groups with various states of vascular complications although the lowest concentration of IMA was observed in patients with microangiopathy. Patients with poor glycemic control had higher IMA level in comparison with these with good glycemic control. Significant correlation was observed between IMA and HbA_{1c}. Among the risk factors, only blood pressure and LDL showed a weak relationship with IMA level.
CONCLUSIONS: Our results revealed, for the first time, higher level of IMA in diabetic patients which confirms that it may be of non-cardiac origin. We can suggest that the albumin molecule in plasma of diabetic patients is modified in the chronic hypoxia conditions provoked mainly by hyperglycemia and oxidative stress in diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688079      PMCID: PMC3850615          DOI: 10.1155/2008/784313

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  27 in total

Review 1.  Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

Authors:  Kazuhiko Kotani; Satoshi Kimura; Alejandro Gugliucci
Journal:  J Physiol Biochem       Date:  2011-04-12       Impact factor: 4.158

2.  Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis.

Authors:  Shao-gang Ma; Yue Jin; Wei Xu; Wen Hu; Feng Bai; Xiao-juan Wu
Journal:  Endocrine       Date:  2012-03-23       Impact factor: 3.633

3.  Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy.

Authors:  V S Reddy; P Agrawal; S Sethi; N Gupta; R Garg; H Madaan; V Kumar
Journal:  Eye (Lond)       Date:  2015-09-18       Impact factor: 3.775

4.  Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers.

Authors:  Maria Gabriela Valle Gottlieb; Ivana Beatrice Mânica da Cruz; Marta M F Duarte; Rafael Noal Moresco; Mário Wiehe; Carla Helena Augustin Schwanke; Luiz Carlos Bodanese
Journal:  J Clin Endocrinol Metab       Date:  2009-12-16       Impact factor: 5.958

5.  A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin.

Authors:  Kubilay Ukinc; Selcuk Eminagaoglu; Halil Onder Ersoz; Cihangir Erem; Caner Karahan; Arif Bayram Hacihasanoglu; Mustafa Kocak
Journal:  Endocrine       Date:  2009-09-26       Impact factor: 3.633

6.  Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus.

Authors:  Rajinder Chawla; Rinchu Loomba; Deepak Guru; Vikas Loomba
Journal:  J Clin Diagn Res       Date:  2016-03-01

7.  Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure.

Authors:  Hamit Yasar Ellidag; Esin Eren; Necat Yılmaz; Yesim Cekin
Journal:  Redox Rep       Date:  2014-01-13       Impact factor: 4.412

8.  Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease.

Authors:  Shao-gang Ma; Chun-ling Wei; Bing Hong; Wei-nan Yu
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  The role of albumin in human toxicology of cobalt: contribution from a clinical case.

Authors:  Simona Catalani; Roberto Leone; Maria Cristina Rizzetti; Alessandro Padovani; Pietro Apostoli
Journal:  ISRN Hematol       Date:  2010-10-31

10.  Serum Ischemia-Modified Albumin, Fibrinogen, High Sensitivity C- Reactive Proteins in Type-2 Diabetes Mellitus without Hypertension and Diabetes Mellitus with Hypertension: A Case-Control Study.

Authors:  Sushith Sushith; Herijenahalli Nagaraju Krishnamurthy; Shridhar Reshma; D'Sa Janice; Gopal Madan; Kumar Jeppu Ashok; Mangalore Balakrishna Prathima; Bhuvanesh Sukhlal Kalal
Journal:  Rep Biochem Mol Biol       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.